Clinical trials
Sexually Transmitted Infections (Not HIV or Hepatitis) clinical trials
Below are recruiting sexually transmitted infections (not hiv or hepatitis) clinical trials, each written for real people, not researchers. We’re tracking 794 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03258567RecruitingPhase 2
Nivolumab for EBV-related lymphomas and abnormal immune illnesses
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
Bethesda, MarylandAges 12 years+ - NCT03178630Recruiting
MRI scans to track outcomes in children with autoimmune liver disease
This study uses MRI scans to find “biomarkers,” or imaging clues, that may help predict how autoimmune liver conditions will progress in children and young adults. If you qualify, you may get MRI imaging to see whether it relates to future health outcomes.
Cincinnati, OhioAges 6–23 - NCT03354728RecruitingPhase 1/Phase 2
Vaccine trial for children with CMV after stem cell transplant
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
Duarte, CaliforniaAges 1–21 - NCT03267615Recruiting
Study in advanced liver scarring using pressure and stiffness tests
This study looks at people over 18 who have advanced, long-term liver scarring. It uses specialized measurements of liver stiffness and pressure to confirm eligibility and may help doctors better understand this condition.
ViennaAges 18–100 - NCT07401862RecruitingPhase 1
Study of Eloralintide in people with different levels of liver damage
This trial tests a new medicine called eloralintide in people with healthy livers and in those with mild, moderate, or severe liver damage. It helps researchers learn how the liver affects the medicine in the body.
Orlando, FloridaAges 18–85 - NCT07412483Recruiting
Dengue infection study in healthy adults
This trial tests how the dengue virus affects healthy adults who have never been exposed to dengue or similar viruses. You would be given a controlled dose of the virus and closely monitored to help researchers understand the infection and develop better treatments or vaccines.
SingaporeAges 21–45 - NCT07418008Recruiting
Thinking and memory study for people with liver cirrhosis
This study is creating a new test to measure thinking and memory problems in people with liver cirrhosis. It may help doctors find these problems earlier.
Ambāla, HaryanaAges 18–75 - NCT07418294Recruiting
Fluctuation imaging for liver hemangioma diagnosis
This study tests a new ultrasound technique called fluctuation imaging to see if it can accurately diagnose hepatic hemangiomas (a common type of non-cancerous liver tumor). If you have a liver spot detected on an ultrasound, this study may help confirm what it is without needing a biopsy.
Seoul, Seodaemun-guAges 19 years+ - NCT07419347Recruiting
Glecaprevir/Pibrentasvir safety in real-world use
This study watches how safe and well-tolerated the 8-week treatment with glecaprevir/pibrentasvir is for people with hepatitis C who are taking other prescription or illicit drugs. It helps doctors learn more about using this medicine in everyday life.
Vancouver, British ColumbiaAges 18 years+ - NCT07431840Recruiting
Immune protein for respiratory infections in older adults
This trial tests whether an immune defense protein can help reduce upper respiratory infections (like colds) in people aged 60 and older. It may be a good fit if you get colds or flu-like symptoms several times each season.
Los Angeles, CaliforniaAges 60 years+ - NCT07445412Recruiting
Liver regeneration study for patients with small future liver remnant
This trial tests techniques to help the liver grow before surgery in people who have a liver tumor and whose future liver remnant is too small. The goal is to make the liver big enough to safely remove the tumor.
Bologna, BolognaAges 18 years+ - NCT07449091Recruiting
HBV undetectable equals untransmissible study
This study checks if having undetectable hepatitis B virus (HBV) means you cannot pass it to others. It tests this idea in people with chronic HBV who are on treatment, those not on treatment, and healthy controls.
New York, New YorkAges 18–65 - NCT07454837RecruitingPhase 2/Phase 3
Switching to brelovitug for chronic hepatitis D patients on bulevirtide
This trial tests if switching from bulevirtide to brelovitug can help people with chronic hepatitis D (CHD). It is for adults who have been on bulevirtide for at least 6 months and still have detectable virus.
GrazAges 18 years+ - NCT07454915RecruitingPhase 2
PVX4 vaccine for HPV16-related cervical dysplasia
This trial tests a new vaccine called PVX4 for women with HPV16-related cervical dysplasia. It aims to see if the vaccine can help clear the high-risk HPV infection and the abnormal cells on the cervix.
The Bronx, New YorkAges 18–60 - NCT07471542Recruiting
Copper supplements for cirrhosis patients
This trial tests whether taking copper supplements can help people with cirrhosis (scarring of the liver) who have low copper levels or symptoms related to copper deficiency. It aims to see if this can improve their health.
Seattle, WashingtonAges 18 years+ - NCT07480824RecruitingPhase 1
Liver function and safety of TQ05105 tablet
This study tests how a tablet called TQ05105 is processed in people with different levels of liver function. It helps doctors understand the right dose for patients with liver problems.
Luoyang, HenanAges 18–75 - NCT07481734RecruitingPhase 2
Tesamorelin for reducing liver fat in fatty liver disease
This trial tests if tesamorelin, a daily injection, can reduce liver fat in adults with fatty liver disease. It may help people whose liver has fat but is not yet scarred into cirrhosis.
Shenzhen, GuangdongAges 18–75 - NCT07486102RecruitingPhase 1
Study of BI 3000202 in people with and without liver problems
This study tests how a new medicine, BI 3000202, is absorbed into the blood. It includes people with different levels of liver function (normal, mild, moderate, or severe) to see if liver problems affect how the medicine works.
San Antonio, TexasAges 18–80 - NCT07378072Recruiting
12-week daytime eating study for fatty liver in obesity
This study tests if restricting eating to daytime hours for 12 weeks can reduce liver fat in people with obesity. It aims to help those with fatty liver disease improve their health without medication.
AngersAges 18–65 - NCT07492147Recruiting
Negative pressure suction for kidney stone surgery
This trial tests if using negative pressure suction during ureteroscopy can reduce fluid absorption and infections. It may help people undergoing kidney stone surgery.
Lanzhou, GansuAges 18 years+ - NCT07492511Recruiting
Ultrasound patterns in kidney and liver after trauma
This trial uses special ultrasound (Doppler) to look at blood flow in the kidneys and liver after a serious injury. It aims to find patterns that could help doctors better understand and treat trauma patients.
BolognaAges 18–65 - NCT07493109RecruitingPhase 3
Maintenance treatment for hepatitis B-related lymphoma after initial therapy
This trial tests whether the drug chidamide, taken after initial successful treatment, can help prevent relapse in people with a type of lymphoma (diffuse large B-cell lymphoma) who also have chronic hepatitis B. Participants must have achieved complete remission after six cycles of standard chemotherapy (R-CHOP).
Changchun, JilinAges 18–80 - NCT07495332Recruiting
Liver imaging study using new biomarkers
This study tests whether a new type of MRI scan can better detect and measure liver disease, including fatty liver and scarring, compared to standard CT scans. If you have chronic liver disease, this study may help improve how we diagnose and track it.
Durham, North CarolinaAges 18 years+ - NCT07517198RecruitingPhase 1
EXS74539 Study for Advanced Solid Tumors
This is an early-stage study testing a new cancer drug called EXS74539 to find the right dose and see how well it works in people with various advanced solid tumors. The drug may help patients whose cancers have stopped responding to standard treatments.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Sexually Transmitted Infections (Not HIV or Hepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sexually transmitted infections (not hiv or hepatitis)?
- Yes. Clin2 currently lists 794 recruiting sexually transmitted infections (not hiv or hepatitis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sexually transmitted infections (not hiv or hepatitis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sexually transmitted infections (not hiv or hepatitis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.